FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125758824> ?p ?o ?g. }

• W2125758824 endingPage "e95180" @default.
• W2125758824 startingPage "e95180" @default.
• W2125758824 abstract "Lysophosphatidic acid (LPA) has been found to mediate myeloid differentiation, stimulate osteogenesis, alter cell proliferation and migration, and inhibit apoptosis in chondrocytes. The effect of LPA on the angiogenic capability of chondrocytes is not clear. This study aimed to investigate its effect on the angiogenic capability of human chondrocytes and the underlying mechanism of these effects. Human chondrocyte cell line, CHON-001, commercialized human chondrocytes (HC) derived from normal human articular cartilage, and human vascular endothelial cells (HUVECs) were used as cell models in this study. The angiogenic capability of chondrocytes was determined by capillary tube formation, monolayer permeability, cell migration, and cell proliferation. An angiogenesis protein array kit was used to evaluate the secretion of angiogenic factors in conditioned medium. Angiogenin, insulin-like growth factor-binding protein 1 (IGFBP-1), interleukin (IL)-8, monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinase (MMP)-9, and vascular endothelial growth factor (VEGF) mRNA and protein expressions were evaluated by Q-RT-PCR and EIA, respectively. LPA receptor (LPAR) expression was determined by RT-PCR. Signaling pathways were clarified using inhibitors, Western blot analysis, and reporter assays. The LPA treatment promoted the angiogenic capability of CHON-001 cells and HC, resulting in enhanced HUVEC capillary tube formation, monolayer permeability, migration, and cell growth. Angiogenin, IGFBP-1, IL-8, MCP-1, MMP-9, and VEGF mRNA and protein expressions were significantly enhanced in LPA-treated chondrocytes. LPA2, 3, 4 and 6 were expressed in CHON-001 and HC cells. Pretreatment with the Gi/o type G protein inhibitor, pertussis toxin (PTX), and the NF-kB inhibitor, PDTC, significantly inhibited LPA-induced angiogenin, IGFBP-1, IL-8, MCP-1, MMP-9, and VEGF expressions in chondrocytes. The PTX pretreatment also inhibited LPA-mediated NF-kB activation, suggesting the presence of active Gi/NF-kB signaling in CHON-001 and HC cells. The effect of LPA on the angiogenesis-inducing capacity of chondrocytes may be due to the increased angiogenesis factor expression via the Gi/NF-kB signaling pathway." @default.
• W2125758824 created "2016-06-24" @default.
• W2125758824 creator A5024024448 @default.
• W2125758824 creator A5025267285 @default.
• W2125758824 creator A5033747954 @default.
• W2125758824 creator A5061353709 @default.
• W2125758824 creator A5076628088 @default.
• W2125758824 creator A5088351761 @default.
• W2125758824 date "2014-05-30" @default.
• W2125758824 modified "2023-10-16" @default.
• W2125758824 title "Lysophosphatidic Acid Enhanced the Angiogenic Capability of Human Chondrocytes by Regulating Gi/NF-kB-Dependent Angiogenic Factor Expression" @default.
• W2125758824 cites W1859112706 @default.
• W2125758824 cites W1986781592 @default.
• W2125758824 cites W1992203600 @default.
• W2125758824 cites W1993235326 @default.
• W2125758824 cites W2002254327 @default.
• W2125758824 cites W2007762330 @default.
• W2125758824 cites W2019122456 @default.
• W2125758824 cites W2021068763 @default.
• W2125758824 cites W2024715415 @default.
• W2125758824 cites W2025930116 @default.
• W2125758824 cites W2028038006 @default.
• W2125758824 cites W2038420555 @default.
• W2125758824 cites W2038846423 @default.
• W2125758824 cites W2042932723 @default.
• W2125758824 cites W2046585688 @default.
• W2125758824 cites W2051737747 @default.
• W2125758824 cites W2052045807 @default.
• W2125758824 cites W2052912009 @default.
• W2125758824 cites W2054349325 @default.
• W2125758824 cites W2054440394 @default.
• W2125758824 cites W2060214931 @default.
• W2125758824 cites W2060539562 @default.
• W2125758824 cites W2063445189 @default.
• W2125758824 cites W2065492096 @default.
• W2125758824 cites W2068361762 @default.
• W2125758824 cites W2074190254 @default.
• W2125758824 cites W2084010197 @default.
• W2125758824 cites W2090843336 @default.
• W2125758824 cites W2114297027 @default.
• W2125758824 cites W2129351604 @default.
• W2125758824 cites W2130033521 @default.
• W2125758824 cites W2134143145 @default.
• W2125758824 cites W2142363848 @default.
• W2125758824 cites W2146242441 @default.
• W2125758824 cites W2147881577 @default.
• W2125758824 cites W2158930668 @default.
• W2125758824 cites W2159623504 @default.
• W2125758824 cites W2172197499 @default.
• W2125758824 cites W2306151829 @default.
• W2125758824 doi "https://doi.org/10.1371/journal.pone.0095180" @default.
• W2125758824 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4039431" @default.
• W2125758824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24879414" @default.
• W2125758824 hasPublicationYear "2014" @default.
• W2125758824 type Work @default.
• W2125758824 sameAs 2125758824 @default.
• W2125758824 citedByCount "18" @default.
• W2125758824 countsByYear W21257588242014 @default.
• W2125758824 countsByYear W21257588242015 @default.
• W2125758824 countsByYear W21257588242016 @default.
• W2125758824 countsByYear W21257588242017 @default.
• W2125758824 countsByYear W21257588242019 @default.
• W2125758824 countsByYear W21257588242020 @default.
• W2125758824 countsByYear W21257588242021 @default.
• W2125758824 countsByYear W21257588242022 @default.
• W2125758824 crossrefType "journal-article" @default.
• W2125758824 hasAuthorship W2125758824A5024024448 @default.
• W2125758824 hasAuthorship W2125758824A5025267285 @default.
• W2125758824 hasAuthorship W2125758824A5033747954 @default.
• W2125758824 hasAuthorship W2125758824A5061353709 @default.
• W2125758824 hasAuthorship W2125758824A5076628088 @default.
• W2125758824 hasAuthorship W2125758824A5088351761 @default.
• W2125758824 hasBestOaLocation W21257588241 @default.
• W2125758824 hasConcept C123012128 @default.
• W2125758824 hasConcept C153911025 @default.
• W2125758824 hasConcept C167734588 @default.
• W2125758824 hasConcept C170493617 @default.
• W2125758824 hasConcept C185592680 @default.
• W2125758824 hasConcept C202751555 @default.
• W2125758824 hasConcept C2775960820 @default.
• W2125758824 hasConcept C2776661833 @default.
• W2125758824 hasConcept C2776719180 @default.
• W2125758824 hasConcept C2777025900 @default.
• W2125758824 hasConcept C2777834122 @default.
• W2125758824 hasConcept C2780394083 @default.
• W2125758824 hasConcept C2781403057 @default.
• W2125758824 hasConcept C49773422 @default.
• W2125758824 hasConcept C502942594 @default.
• W2125758824 hasConcept C55493867 @default.
• W2125758824 hasConcept C62112901 @default.
• W2125758824 hasConcept C62478195 @default.
• W2125758824 hasConcept C80631254 @default.
• W2125758824 hasConcept C86803240 @default.
• W2125758824 hasConcept C95444343 @default.
• W2125758824 hasConceptScore W2125758824C123012128 @default.
• W2125758824 hasConceptScore W2125758824C153911025 @default.
• W2125758824 hasConceptScore W2125758824C167734588 @default.
• W2125758824 hasConceptScore W2125758824C170493617 @default.

• next